Merck & Co. stock gains on dividend and analyst support
Published on 09/17/2026 at 14:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co., Inc. stock (ISIN US58933Y1055) is trading close to its recent highs, with the shares closing at USD 144.88 on the New York Stock Exchange on September 16, 2026, supported by a new quarterly dividend and resilient analyst sentiment.
Dividend and recent performance
According to Yahoo Finance, Merck announced a cash dividend of USD 0.85 per share with an ex-dividend date of September 15, 2026, which translates to USD 3.40 annually and underpins a yield of roughly 2.3 percent at the current share price.
On the latest completed trading day, Merck & Co. stock closed at USD 144.88 on the NYSE at 3:59 p.m. Eastern, up 0.75 percent for the session, with an extended trading indication of USD 144.70 shortly after the close on September 16, 2026, per MarketBeat.
Earnings pressure despite solid revenue
Merck’s latest reported quarter for fiscal year 2026 is the second quarter, covering Q2 FY26, and it shows a mixed picture for investors. In this quarter, Merck generated revenue of USD 16.61 billion, but recorded a GAAP net loss of USD 1.33 billion, corresponding to a profit margin of minus 8.04 percent, as reported by Yahoo Finance.
The comparison with the prior year underlines the current earnings pressure. For the same quarter a year earlier, Merck had GAAP net income of USD 4.43 billion, or USD 1.76 per share, whereas Q2 FY26 swung to a loss of USD 1.34 billion, or USD 0.54 per share, according to Barchart. Adjusted earnings also deteriorated, moving from a profit of USD 2.13 per share to an adjusted loss of USD 0.13 per share in Q2 FY26.
Consensus expectations reflect this weaker earnings phase. For the current quarter ending September 2026, analysts on Yahoo Finance forecast average earnings per share of USD 2.21, with current year 2026 EPS estimated at USD 2.75, down about 69 percent from the prior year EPS level.
Analyst ratings and price targets
Despite earnings volatility, Merck & Co. stock continues to enjoy broadly positive analyst coverage. On September 10, 2026, HSBC raised its price target on Merck stock to USD 172 from USD 150 while maintaining a Buy rating, according to Barchart.
As the same article notes, Leerink Partners also lifted its view, increasing its price target from USD 127 to USD 161 on September 9, 2026 and keeping an Outperform rating on Merck & Co. stock, signaling confidence in the long-term pipeline despite near-term earnings headwinds.
Across Wall Street, Merck has a consensus rating of Moderate Buy based on about 28 analysts, with an average price target of USD 154.96, which implies roughly 8 percent upside from current levels per Barchart. A separate overview of pharmaceutical stocks on MarketBeat shows Merck with a consensus rating score of 2.68, classed as Moderate Buy, and a consensus price target of USD 151.32, corresponding to about 5 percent upside versus the latest closing price.
Market valuation and risk perspective
The strong share performance in 2026 has pushed Merck’s valuation higher. A recent analysis by GuruFocus points out that Merck’s GF Value indicator stands at USD 120.13 compared with a current share price around USD 143.96, suggesting the stock is approximately 19.8 percent overvalued on that metric.
Year-to-date, Merck & Co. stock has still rewarded shareholders with strong returns. According to Barchart, the shares are up about 36 percent in 2026, significantly ahead of the Nasdaq Composite index’s roughly 12 percent gain over the same period, underscoring the market’s appetite for Merck’s defensive profile and pipeline exposure.
At the same time, the combination of negative GAAP earnings in Q2 FY26 and the perception of a 19.8 percent overvaluation on GF Value means investors need to weigh solid cash returns and analyst support against valuation risk and earnings volatility when considering Merck & Co. stock.
Upcoming catalysts and stock level
Looking ahead, a key near-term catalyst will be Merck’s next quarterly earnings release. Merck is set to report its next quarterly results on October 29, 2026, and analysts expect earnings of USD 2.27 per share for the September quarter, down about 12 percent from USD 2.58 per share a year earlier, according to Barchart.
In the market, Merck & Co. stock most recently changed hands at around USD 144.77 on NYSE on September 16, 2026, giving the company a market capitalization of roughly USD 357.67 billion, per Robinhood. For investors, this level marks a price that is close to consensus targets, leaving the upcoming October earnings report and further pipeline developments as important drivers of whether Merck & Co. stock can extend its 2026 outperformance.
Merck & Co. stock at a glance
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- Ticker: MRK
- Trading venue: NYSE
- Price (as of September 16, 2026, 15:59): 144.88 USD
- Market capitalization: 357.67 billion USD (as of September 16, 2026)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: S&P 500
- Next earnings date: October 29, 2026
